1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Legislation

Omnibus Funding Bill Provides Provisions For Future Pandemic Preparedness

 
• By Hannah Daniel

As a part of the end-of year omnibus bill, BARDA and FDA received funding to boost US’s domestic manufacturing of biomedical devices to prepare for future pandemics.

• Source: Shutterstock

The Biomedical Advanced Research and Development Authority (BARDA) will receive a nearly $1bn boost from the omnibus spending bill passed at the end of 2022 as a part of an initiative to prepare for future pandemics.

BARDA will collaborate with the US Food and Drug Administration to create a base of manufacturers that can spring into action if demand for medical device product surges, as might...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Policy & Regulation

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By Elizabeth Orr

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.